SAFE-N-MEDTECH, a new European H2020 NMBP (Nanotechnologies, Advanced Materials, Biotechnology and Advanced Manufacturing and Processing) medtech project, has been launched. BioWin has joined this project as a third party through the Council of European BioRegions (CEBR).
This is an opportunity to integrate a future hub of more than 30 medtech partners. BioWin will contribute to the hub’s dissemination and creation.
SAFE-N-MEDTECH will build an innovative open access platform providing reference laboratories and companies with the capabilities, know-how, networks and services needed for developing, testing, evaluating, optimizing and marketing nanotechnology and diagnostic medical devices throughout the products’ entire lifecycle.
This platform will give SMEs, healthcare providers and industries a novel, multi-disciplinary, market-driven approach based on in-depth understanding and knowledge of materials, property, advanced uses and applications in the medtech sector.